CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 64 enrolled
Drug / intervention
WT2725biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01621542
NCT01621542Phase 1Completed
CompareCT.gov

Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies

Sumitomo Pharma America, Inc.·interventional·Posted Jun 18, 2012·Updated Jul 17, 2019

In Brief

A Phase 1 clinical trial evaluating WT2725 for Cancer. Completed, enrolled 64 participants across 6 sites.

Detailed Summary

This clinical study is designed to evaluate the safety, immunogenicity and antitumor activity of WT2725. WT2725 will be administered to patients with advanced malignancies known to overexpress WT1

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesUnited States
CollaboratorsSumitomo Pharma Co., Ltd.

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJun 18, 2012
Enrollment StartJul 31, 2012
Primary CompletionMay 17, 2017
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 14.0 years ago

Interventions

WT2725biological

WT2725 injection Study drug will be administered every 1-4 weeks